Recent changes in the pharmaceutical industry have spurred an unprecedented wave of mergers and acquisitions. Some researchers and agencies have questioned whether pharmaceutical consolidation could impede drug innovation. However, as I explain in this Article, these concerns are largely based...

Pharmacy benefit managers (PBMs) manage the drug benefits for over 95 percent of Americans with prescription drug coverage. However, conflicts of interest inherent in the PBM business model create perverse incentives for drug price increases. The most significant conflict of interest arises from...

Biologic drugs represent an important category of drugs that improve health outcomes in this country. Yet, these cutting-edge drugs are often prohibitively costly, preventing access for many Americans. Recognizing the need for more affordable, generic substitutes for biologic drugs — or...